News UCB brings first therapy for rare disease TK2d to EU The EU has approved UCB's Kygevvi for rare disease TK2d, and Sanofi's acute GvHD therapy Rezurock, in a pair of decisions announced this morning.
News UCB closes on first EU OK for TK2d therapy UCB gets an EU recommendation for the first therapy for thymidine kinase 2 deficiency (TK2d), plus other CHMP decisions.
News CHMP backs first drug for lung disease bronchiectasis Insmed gets EU recommendation for first non-cystic fibrosis bronchiectasis therapy Brinsupri, plus other CHMP decisions.
News Major trial launched to explore GLP-1 benefit in dementia A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.